SMYD2 and breast cancer: Overexpression of SMYD2 is associated with poor prognosis for patients with cancer, such as gastric, bladder, colon, and breast cancers (BCs), along with esophageal squamous-cell carcinoma, hepatocellular carcinoma, and acute lymphoblastic leukemia9–13.